As expected, APH treatment significantly increased the numbers of CFS-associated UFBs in CDA-proficient and CDA-deficient cells, as shown by FANCD2 immunostaining (Supplementary Fig. 4f, g). The gene discussed is FANCD2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.